Amneal enters into a licensing agreement with kashiv biosciences, llc to develop and commercialize k127 for the treatment of myasthenia gravis

Amneal enters into a licensing agreement with kashiv biosciences, llc to develop and commercialize k127 for the treatment of myasthenia gravis.amneal pharmaceuticals inc - amneal gains exclusive rights within united states to new drug application (nda) and commercialization of k127.amneal pharmaceuticals - under terms kashiv will be responsible for all development, clinical work required to secure fda approval.amneal pharmaceuticals - kashiv will receive upfront payment of $1.5 million & is eligible to receive development & regulatory milestones of $16.5 million.
AMRX Ratings Summary
AMRX Quant Ranking